Moderna, Merck cancer vaccine hits key Phase 3 endpoints
Moderna and Merck say their personalized mRNA cancer vaccine intismeran with Keytruda met key endpoints in a Phase 3 melanoma trial, cutting recurrence and distant metastasis versus Keytruda alone.